Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand

Sanofi Pasteur SA0 个研究点目标入组 4,002 人开始时间: 2014年5月26日最近更新: 2014年6月2日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 4,002

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1) Aged 4 to 11 years on the day of inclusion.
•2) Subject in good health, based on medical history and physical examination.
•3) Provision of assent form signed by the subject (for subjects = 7 years old) and informed consent form signed by the parent or another legally acceptable representative.
•4) Subject and parent/legally acceptable representative able to attend all scheduled visits and to comply with all trial procedures.
•5) Subject attending one of the schools involved in the trial and living in the Ratchaburi Province.
•6) For a female subject of child-bearing potential (girls post-menarche), avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to first vaccination, until at least 4 weeks after the last vaccination.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 4002
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•1) Febrile illness (temperature = 37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment.
•2) For a female subject of child-bearing potential (girls post-menarche), known pregnancy or positive urine pregnancy test on the day of the first trial vaccination.
•3) Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.
•4) Planned participation in another clinical trial during the present trial period.
•5) Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy, or long-term systemic corticosteroids therapy.
•6) Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccines or to a vaccine containing any of the same substances.
•7) Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.
•8) Receipt of blood or blood-derived products in the past 3 months.
•9) Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
•10) Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.
•11) Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.
•12) Planned receipt of any vaccine in the 4 weeks following the first trial vaccination.
•13) Subject who planned to attend another school (outside the trial area) or move to another city in the coming 30 months.

研究者

发起方

Sanofi Pasteur SA

相似试验

进行中（未招募）

不适用

Study of Sanofi Pasteur's Dengue Vaccine in Healthy Children Aged 2 to 11 Years in MalaysiaPrevention of symptomatic dengue disease

EUCTR2014-001717-11-Outside-EU/EEASanofi Pasteur SA250

进行中（未招募）

不适用

Study of Sanofi Pasteur's Dengue Vaccine in Healthy Children and Adolescents in South AmericaPrevention of symptomatic dengue disease

EUCTR2014-001715-39-Outside-EU/EEASanofi Pasteur SA150

已完成

2 期

Efficacy and Safety of Dengue Vaccine in Healthy ChildrenDengue VirusDengue DiseasesDengue FeverDengue Hemorrhagic Fever

NCT00842530Sanofi Pasteur, a Sanofi Company4,002

进行中（未招募）

不适用

Study of Sanofi Pasteur's dengue vaccine in healthy toddlers Aged 12 to 15 Months in the PhilippinesPrevention of symptomatic dengue disease

EUCTR2014-001694-14-Outside-EU/EEASanofi Pasteur SA210

已完成

2 期

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive AdultsDengue Hemorrhagic FeverHuman Immunodeficiency VirusDengue Fever

NCT02741128Sanofi Pasteur, a Sanofi Company133